APP and Alzheimer disease: For example, breviscapine combined with BMSC therapy activates NF-κB to promote ubiquitin carboxyl-terminal hydrolase L1 expression, reduces Aβ deposition in AD rats, and facilitates the degradation of amyloid precursor protein and β-site APP-cleaving enzyme 1 [85].